组织蛋白酶D检测在乳腺癌组织中的临床意义
Clinical significance of cathepsin D assay in breast cancer tissues.
作者信息
Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A
机构信息
Second Department of Surgery, Nagoya City University Medical School, Japan.
出版信息
J Surg Oncol. 1995 Dec;60(4):221-6. doi: 10.1002/jso.2930600402.
Cathepsin D was assayed in 74 primary breast cancer specimens by enzyme immunoassay (EIA) and immunohistochemical assay (ICA). Of the 74 specimens, 38 (51.4%) were scored positive by ICA, and 25 (33.8%) were scored positive by EIA. The coincidence rate between ICA and EIA was 71.6% (53/74). There was no significant correlation between cathepsin D and menopausal status, tumor size, number size, number of metastatic lymph nodes, histological type of the tumor, or steroid receptor status. Cathepsin D status designated by EIA or ICA predicted neither disease-free survival (DFS) nor overall survival (OAS). Subject analysis with estrogen receptor, menopausal, and lymph node status revealed no association between cathepsin D and DFS or OAS. Therefore, cathepsin D is not an independent prognostic factor in breast cancer.
采用酶免疫测定法（EIA）和免疫组织化学测定法（ICA）对74份原发性乳腺癌标本中的组织蛋白酶D进行了检测。在这74份标本中，38份（51.4%）经ICA检测为阳性，25份（33.8%）经EIA检测为阳性。ICA与EIA之间的符合率为71.6%（53/74）。组织蛋白酶D与绝经状态、肿瘤大小、数量、转移淋巴结数量、肿瘤组织学类型或类固醇受体状态之间无显著相关性。由EIA或ICA确定的组织蛋白酶D状态既不能预测无病生存期（DFS），也不能预测总生存期（OAS）。对雌激素受体、绝经和淋巴结状态进行的亚组分析显示，组织蛋白酶D与DFS或OAS之间无关联。因此，组织蛋白酶D不是乳腺癌的独立预后因素。
Zotero 插件